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ABSTRACT
Mother-to-child transmission of human immune deficiency virus (HIV) is a multifactorial event
highly associated with advanced maternal HIV disease and obstetric incidents taking place during
parturition. Thus, various approaches to prevention may be beneficial. Although the time and the
route of materno-fetal HIV transmission are still not sufficiently clear, much speaks in favor of a
late HIV transmission, most probably taking place during parturition or the phase before the
delivery. The fetus is remarkably protected by the placenta and the intact fetal membranes against
many viral infections during gestation. These conditions change at parturition and the chance for
a transition of HIV-infected carrier cells or virus into the fetal compartment increases. Proinflam-
matory cytokines secreted at the materno-fetal interface accumulate in amniotic fluid and may
chemoattract and stimulate potentially HIV-infected immunocytes. After rupture of membranes,
maternal cells of the decidua are directly exposed to the amniotic fluid. Aside from the contamina-
tion of the fetal skin at vaginal delivery as a debatable route of infection, blood-to-blood contacts and
the fetal swallowing of contaminated amniotic fluid may be the major path of fetal HIV infection.
For the fetal prophylaxis of an intrauterine infection, the application ofzidovudine is recommended.
However, cesarian section before the onset of labor leads also to a diminution of the transmission
rate. As the transmission seems to have both systemic and local causes, it makes sense to combine
different intervention strategies. Whether a combination ofzidovudine and elective cesarean section
can lower the transmission risk further has to be evaluated. Infect. Dis. Obstet. Gynecol. 5:115-120,
1997. (C) 1997 Wiley-Liss, Inc.
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ore than 10 years after the first report on
AIDS symptoms in children born to HIV-
infected mothers, the time and the route of
materno-fetal HIV transmission are still not suffi-
ciently clear. For a rational prevention this raises a
considerable problem and is crucial for an effective
design of intervention to reduce transmission. The
transmission may occur during three phases: in
utero during gestation, intrapartum at parturition
and delivery, and postpartum through breastfeed-
ing. From a pediatric view, much is in favor of a late
HIV transmissione,3 most probably taking place
during parturition or within two months before the
delivery.4
RISK FACTORS FOR
VERTICAL TRANSMISSION
HIV-Associated Factors
The risk factors for materno-fetal HIV transmission
are either HIV-associated and related to the im-
mune reaction of the mother to the HIV infection
or associated with events taking place during par-
turition. The HIV-associated parameters refer to an
advanced or rapidly progressing HIV infection of
the mother. The obstetric risks refer to the process
of labor and delivery and particularly its pathology
(Table 1). A transmission of the virus happens
more easily if an advanced HIV infection of the
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TABLE I. Risk factors for materno-fetal HIV transmission
HIV-associated risks of the mother Obstetrically associated risks
--Advanced or quick progressive HIV infection as well as rapid
postpartum progression to AIDS
--Increased HIV viremia
mlncreased number of HIV-RNA
mlncreased p24 antigenemia
--Reduced CD4 cell numbers
--Low neutralizing antibody
--Macrophage-associated HIV variants
--Therapeutic abortion
--Premature birth and preterm labor
mVaginal delivery
--Long duration of vaginal delivery
--Time of rupture of membranes before delivery
Hemorrhage and bloody amniotic fluid
Chorioamnionitis
mPrevious (first) twin
mother was already clinically obvious,s if increasing
concentrations of p24 antigen can be detected in
the maternal serum or if free virus is proven more
frequently,6,7 and increased level of HIV-RNA can
be discovered,8 and a decrease of CD4+ lympho-
cytes is found,s
Further risks of infection consist in the genesis
of definite virus variants,9 an influence of the HIV
cell tropism on maternal monocytes/macrophages
as well as the susceptibility of fetal target cells.1 In
addition, the absence of definite MHC II allele
among Africans and Hispanics may give an ethni-
cally justified reason for the increased risk for HIV
of the newborns of these groups. 11
Low titers of anti-p24le and neutralizing anti-
bodies may correlate with an increased risk of
transmission. 13,4 This could not be confirmed in
other investigations.s,6 A peripheral viremia as a
causal factor of virus transmission is judged contra-
dictorily,e and similar controversies are indicated
also for the HIV-RNA copy number as predictor of
the materno-fetal HIV transmission. 7,18
This limits both the possibility of a causal as-
signment and the judgment of the valency of these
HIV-associated parameters as predictors for the
risk of materno-fetal transmission.
Obstetric Factors
One of the systemic changes of an advanced HIV
infection is the multiplied incidence of HIV-DNA
carrying cells in the maternal organism and the in-
dividual tissues. Correspondingly the prevalence of
HIV-DNA in the endometrium is increased.9 The
endometrium and primarily the decidua are rich in
monocytes/macrophages which are considered as
head reservoir for a transmission of HIV to fetal
target cells,e This may represent a local and pri-
marily functional interface between HIV-related
and obstetric risks. Therapeutic abortion,e prema-
ture birth and preterm labor increase the risk of
HIV infection of the fetus or newborn,ee An infec-
tion of the fetal membranes also increases the
transmission risk.z3 The frequency of chorioamni-
onitis may be considered as a reason for the higher
vertical transmission rates in developing coun-
tries,z4
However, breastfeeding must be considered also
as an important postnatal source of infection in
these countries,zs The meaning of parturition as a
serious risk of vertical HIV transmission gets sup-
port by the association between transmission risk
and duration of rupture of fetal membranes before
delivery,z6 Birth-relevant or local factors must be
considered also as an explanation for the discrep-
ancy of the materno-fetal transmission to twins,
since the first twin shows a clearly higher risk for
infection, e7
Although the initial steps of the genesis of labor
and parturition are not fully clear yet, there is
agreement that the materno-fetal interface layer is
involved in this process and activated during par-
turition. The activation of interface cells of chorion
and decidua resembles inflammatory or traumatic
reactions, es,z9 The secretion of proinflammatory
cytokines such as interleukin (IL)-I and IL-6 is
remarkably enhanced particularly in the proximity
of the cervix. These cytokines are either chemoat-
tractive for potentially HIV-infected immunocytes
or can stimulate the HIV synthesis in these cells.
Although the fetus is highly protected by the
intact fetal membranes against many viral infec-
tions during gestation, these conditions change at
parturition, and the chance for a transition of HIV-
infected carrier cells or virus into the fetal compart-
ment increases. At a rupture of membranes, the
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FETAL MEMBRANES
CERVIX
VAGINA
Fig. I. Possible routes of materno-fetal HIV transmission. I. Direct access of free virus (a) or HIV DNA carrying cells (b)
to fetal bloodstream by microhemorrhagia in the placenta. 2. Generation of an infectious chain by infection of Hofbauer cells
or trophoblast cell and following infection of the fetus. 3. Fetal swallowing of amniotic fluid contaminated with free virus (a)
or HIV DNA carrying cells (b) in the sequel of activation of the fetomaternal interface in labor or rupture of membranes. 4.
Accessibility via microlesions of the skin during vaginal delivery?
risk climbs, and maternal cells of the decidua are
directly exposed to the amniotic fluid. Consider-
able amounts of amniotic fluid are then held back
behind the fetal head. During gestation and even
during parturition the fetus is continuously swal-
lowing amniotic fluid. An oral or gastrointestinal
absorption of HIV-contaminated amniotic fluid is
an efficient path of infection of newborn mon-
keys.’2 An infection by an external contamina-
tion during vaginal delivery is less probable since
the cleansing of the birth channel does not repre-
sent any efficient measure of prevention.3 HIV
transmission via the placenta subsequent to
materno-fetal microtransfusion particularly at labor
or as part of an infection chain of placenta cells
should be unchangedly kept in mind.4,s (Fig-
ure 1).
INTERVENTION TO DECREASE
MATERNO-FETAL HIV TRANSMISSION
Obstetric Intervention
Given the known obstetric risks, the influence of
local events at the materno-fetal interface espe-
cially at parturition must be taken into account as
important causes for peripartum materno-fetal
transmission. After the benefit of elective cesarean
section first intuitively chosen by many obstetri-
cians was questionable, metaanalysis showed a
diminution of materno-fetal HIV transmission by
cesarean section.36 Different studies suggested that
a well-timed cesarean section must be considered
as effective infection prophylaxis,37,3s This proce-
dure has been and is still not uncontradicted. The
European Collaborative Study of 1992 did not
show any advantage of "elective caesarean" over
the vaginal delivery,s A reassessment of the Euro-
pean study yielded however a moderate diminu-
tion of materno-fetal transmission with cesarian
section.39 French study did not show any benefit of
"elective cesarean" or "emergency cesarean;"
however, simultaneously the study indicated a de-
pendence on the duration of the rupture of mem-
brane before birth, bloody amniotic fluid and hem-
orrhage in labor.4 Because of the conflicting
results from observational studies regarding the ef-
fect of the mode of delivery on materno-fetal trans-
mission, cesarean section is not routinely recom-
mended, and a randomized clinical trial is under-
way in Europe to evaluate the effectiveness of
cesarean section. By definition, an elective or pri-
mary cesarean section has to be done before the
onset of labor. In that respect the aim is not only
the avoidance of a vaginal delivery but also of fetal
exposure to the process of parturition and concomi-
tant events, such as duration of rupture of mem-
branes, bloody amniotic fluid, etc. From an obstet-
ric view, the elective cesarean should reduce these
risks, if an atraumatic surgical technique and ad-
equate precautions against fetal contamination are
taken. For example, since the fetal risk of infection
by oral absorption of HIV must be considered se-
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TABLE 2. Combined intervention of vertical HIV transmission with zidovudine and caesarean section
Week of gestation 16th-32nd >32nd -37th Newborn postnatum
Asymptomatic HIV infection
and no pretreatment
HIV-associated risk
(e.g., progressed
HIV infection)
Obstetric risk (e.g.,
preterm labor)
Zidovudine
5 x 100 mg
Zidovudine Zidovudine infusion Zidovudine 4 x 2
5 x 100 mg (2 mg/kg/h) and mg/kg for 10 days
elective cesarean
Zidovudine Zidovudine infusion Zidovudine 4 x 2
5 x 100 mg (2 mg/kg/h) and mg/kg for 10 days
elective cesarean
Zidovudine Zidovudine Zidovudine 4 x 2
5 x 100 mg and infusion (2 mg/kg/h) mg/kg for 10 days
tocolysis and cesarean section
riously, it may be important to avoid contamination
of amniotic fluid with maternal blood before having
lifted the fetal head superiorly through the uterine
and abdominal incision.
Antiretroviral Drugs
The convincing data of the AZT (azidothymidine)
study offers the obstetrician, moreover, a further
alternative.41 However, it is not yet clear when
therapy is meaningful: throughout pregnancy, in
the last phase of gestation, or only at labor and
during the delivery. Neither the time of the opti-
mal beginning of therapy nor the causal pharmaco-
logical attempt are clear so as to decrease the trans-
mission rate. Uncertainties exist also concerning
the duration of postpartum treatment of the new-
born. An application of zidovudine for six weeks is
a long time in view of the apparently short surviv-
ability of HIV in the serum.42 There are in addition
notes that a postpartum treatment of the newborn
brings no essential advantage if the mother had
received zidovudine already during gestation.43
Expectations increasing the prevention efficiency
by using more nucleoside analogs are reasonable
but have not yet been proven. Even if a terato-
genicity can be excluded largely, caution is advis-
able since nucleoside analogs can have a mutagenic
potential and may have late manifestations like ma-
lignomas. Therefore, obstetricians and pediatri-
cians are careful with excessive use of antiretroviral
medications in view of the relatively low European
transmission rates of about 14%. Possible delayed
effects of antiretroviral medications cannot be ef-
fectively excluded in the case of long-term therapy
during pregnancy and the postnatal period. Fur-
thermore, a rapid development of zidovudine re-
sistance is possible. Even if peripheral parameters
like the numbers ofHIV-RNA copies certainly rep-
resent a potent marker for a globally increased risk,
it remains questionable if virus burden under anti-
retroviral therapy may be useful as a reliable risk
assessment for materno-fetal HIV transmission.
Therefore, the generous use of antiretroviral com-
bination therapies must be viewed critically, par-
ticularly if it restricts the reflection of the indi-
vidual risk of the mother for a materno-fetal HIV
transmission only on the height of the peripheral
"virus burden" neglecting the coexistence of ob-
stetric events.
Combination of Obstetric
and Drug Intervention
For the fetal prophylaxis of an intrauterine infec-
tion the application of zidovudine during gestation
and parturition is clearly recommended. Despite all
controversies there is a general agreement in Ger-
many to perform an elective cesarean section at the
latest in the 37th week of gestation for HIV-
infected pregnant women. However, both mea-
sures provide merely a diminution of the transmis-
sion rate. As the transmission seems to have both
systemic and local causes, it makes sense to com-
bine the intervention strategies.
Following these considerations a modified com-
bination of the ACTG 076 protocol and cesarean
section before the onset of labor are carried out in
most obstetric centers in Germany. If there is no
other imperative maternal indication, systemic an-
tepartum prophylaxis with zidovudine is started at
the 32 or 33rd week of gestation (5 x 100 mg AZT)
up to delivery when elective cesarean before the
beginning of the 38th week of pregnancy is carried
out under intravenous application of zidovudine (2
mg/kg/H AZT loading dose).
If a maternal indication is present as, e.g., a pro-
gressed maternal HIV infection or other clinical
symptoms of the HIV infection, the antiretroviral
prophylaxis is started before the 32nd week from a
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therapeutical viewpoint (Table 2). If the woman is
already receiving antiretroviral medication, the
regimen is continued during pregnancy. At preterm
labor before the 33rd week of gestation tocolytic
treatment is required and zidovudine application is
started. A cesarean section under intravenous ap-
plication of zidovudine is carried out immediately
when preterm labor occurs later in pregnancy. With
regard to the debatable benefit of a postpartum
prophylaxis the newborn receives zidovudine only
for ten days (1,3 mg/kg four times a day). Whether
this combination of zidovudine and elective cesar-
ean section can lower the transmission risk further
is currently being studied.
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